Colestipol Hydrochloride NDC 59762-0450

NDC codes

FDA NDC Directory

Product NDC (as listed)59762-0450Labeler and product segments. Claims need a package NDC.

Product NDC at billing width59762-0450Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
59762-0450-1	59762045001	120 TABLET in 1 BOTTLE (59762-0450-1)Marketed from Jul 19, 1994

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Colestipol Hydrochloride
Generic name (nonproprietary): colestipol hydrochloride
Active ingredients: Colestipol hydrochloride — 1 g/1
Dosage form: Tablet
Route: Oral
Labeler: Mylan Pharmaceuticals Inc.
Product type: Prescription drug
Marketing category: NDA authorized genericApplication NDA 020222
Marketing start: Jul 19, 1994
Listing expires: Dec 31, 2026
Other FDA classes: Bile-acid Binding Activity (Mechanism)
Identifiers: Product ID 59762-0450_1b610c4a-a8dc-4a10-bd7a-3e94ca49ee9cSPL ID 1b610c4a-a8dc-4a10-bd7a-3e94ca49ee9cSPL set ID dae7d51e-c117-4c8a-b018-45b01ae46100RxCUI 1048445UNII X7D10K905G
Pharmacologic class: Bile Acid Sequestrant

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N459762045001 followed by a unit qualifier and the quantity

Package 59762-0450-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective May 13, 2025.

Indications (excerpt from the label)

INDICATIONS AND USAGE Since no drug is innocuous, strict attention should be paid to the indications and contraindications, particularly when selecting drugs for chronic long-term use. Colestipol hydrochloride tablets are indicated as adjunctive therapy to diet for the reduction of elevated serum total and LDL-C in patients with primary hypercholesterolemia (elevated LDL-C) who do not respond adequately to diet. Generally, colestipol hydrochloride tablets have no clinically significant effect on serum triglycerides, but with their use, triglyceride levels may be raised in some patients. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those ind…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under NDA 020222

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 020222
Product	Strength	Form · route	Labeler	Product NDC
Colestidcolestipol hydrochloride	Colestipol hydrochloride 1 g/1	TabletOral	Pharmacia & Upjohn Company LLC	0009-0450